相关实验视频
Updated: Jun 12, 2025
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.4K
设计第一个预防帕金森病的试验
Grace F Crotty1,2,3, Samuel J Ayer1, Michael A Schwarzschild1,2
1Molecular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
Journal of Parkinson's disease
|September 20, 2024
概括
帕金森病 (PD) 研究正在转向针对疾病早期阶段的二次预防试验. 生物标志物和遗传学的进步使得识别高风险个体能够用于新的治疗干预措施.
科学领域:
- 神经科学是一个神经科学.
- 临床试验 临床试验
- 生物标志物 生物标志物
背景情况:
- 从历史上看,帕金森病 (PD) 研究的重点是第三级预防 (在诊断后减缓进展).
- 最近的科学进步已经揭示了前期的PD阶段,遗传学和生物标志物.
- 这一进展使得我们能够转向早期的干预策略.
研究的目的:
- 审查帕金森病中现有的疾病修饰疗法 (DMT) 试验.
- 总结突破,使得二次预防高风险队列的识别.
- 概述PD二次预防试验的关键设计元素,针对prodromal阶段.
主要方法:
- 对帕金森病目前和过去的DMT试验的审查.
- 对PD前期阶段,遗传学和生物标志物的科学文献分析.
- 对二次预防试验的设计考虑的综合,包括招生,干预和结果措施.
主要成果:
- 对于PD的二次预防试验的出现是迫在眉的,针对临床诊断前高风险的个体.
- 目前正在建立这些试验的关键设计元素,重点关注特定的产卵期阶段.
- 方法方面的挑战仍然存在,但早期干预的机会正在扩大.
结论:
- 科学进步正在为预防帕金森病提供切实的前景.
- 二次预防试验代表了PD治疗开发的重大进展.
- 共同努力对于应对挑战和实现早期PD干预的潜力至关重要.
相关概念视频
01:24Parkinson's Disease: Treatment
235
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
235
01:15Parkinson's Disease: Overview
495
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
495